1180 related articles for article (PubMed ID: 17694447)
1. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
2. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
3. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
[TBL] [Abstract][Full Text] [Related]
5. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
Kinouchi N; Ohsawa Y; Ishimaru N; Ohuchi H; Sunada Y; Hayashi Y; Tanimoto Y; Moriyama K; Noji S
Gene Ther; 2008 Aug; 15(15):1126-30. PubMed ID: 18323791
[TBL] [Abstract][Full Text] [Related]
6. A non-covalent peptide-based strategy for siRNA delivery.
Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
[TBL] [Abstract][Full Text] [Related]
7. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP
Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
[TBL] [Abstract][Full Text] [Related]
8. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
[TBL] [Abstract][Full Text] [Related]
9. Short interfering RNA (siRNA): tool or therapeutic?
Cejka D; Losert D; Wacheck V
Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
[TBL] [Abstract][Full Text] [Related]
10. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
11. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
Singh SK; Hajeri PB
Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
[TBL] [Abstract][Full Text] [Related]
12. Hydrodynamic delivery protocols.
Rychahou PG; Evers BM
Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
[TBL] [Abstract][Full Text] [Related]
13. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
[TBL] [Abstract][Full Text] [Related]
14. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
[TBL] [Abstract][Full Text] [Related]
15. SiRNA delivery: challenges and role of carrier systems.
Shegokar R; Al Shaal L; Mishra PR
Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
[TBL] [Abstract][Full Text] [Related]
16. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of RNA interference against cancer.
Takeshita F; Ochiya T
Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
[TBL] [Abstract][Full Text] [Related]
18. Targeted lipoplexes for siRNA delivery.
Cardoso A; Trabulo S; Moreira JN; Düzgüneş N; de Lima MC
Methods Enzymol; 2009; 465():267-87. PubMed ID: 19913172
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
Malek A; Tchernitsa O
Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
[TBL] [Abstract][Full Text] [Related]
20. Efficient and targeted delivery of siRNA in vivo.
Shim MS; Kwon YJ
FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
